1037 related articles for article (PubMed ID: 33915284)
1. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Assi R; Evrenoglou T; Buckley BS; Henschke N; Probyn K; Riveros C; Davidson M; Graña C; Bonnet H; Jarde A; Ávila C; Nejstgaard CH; Menon S; Ferrand G; Kapp P; Breuer C; Schmucker C; Sguassero Y; Nguyen TV; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Chaimani A; Boutron I
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013881. PubMed ID: 37260086
[TBL] [Abstract][Full Text] [Related]
5. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
Juul S; Nielsen EE; Feinberg J; Siddiqui F; Jørgensen CK; Barot E; Holgersson J; Nielsen N; Bentzer P; Veroniki AA; Thabane L; Bu F; Klingenberg S; Gluud C; Jakobsen JC
PLoS One; 2021; 16(3):e0248132. PubMed ID: 33705495
[TBL] [Abstract][Full Text] [Related]
6. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
7. Systemic corticosteroids for the treatment of COVID-19.
Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
[TBL] [Abstract][Full Text] [Related]
11. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
; Shankar-Hari M; Vale CL; Godolphin PJ; Fisher D; Higgins JPT; Spiga F; Savovic J; Tierney J; Baron G; Benbenishty JS; Berry LR; Broman N; Cavalcanti AB; Colman R; De Buyser SL; Derde LPG; Domingo P; Omar SF; Fernandez-Cruz A; Feuth T; Garcia F; Garcia-Vicuna R; Gonzalez-Alvaro I; Gordon AC; Haynes R; Hermine O; Horby PW; Horick NK; Kumar K; Lambrecht BN; Landray MJ; Leal L; Lederer DJ; Lorenzi E; Mariette X; Merchante N; Misnan NA; Mohan SV; Nivens MC; Oksi J; Perez-Molina JA; Pizov R; Porcher R; Postma S; Rajasuriar R; Ramanan AV; Ravaud P; Reid PD; Rutgers A; Sancho-Lopez A; Seto TB; Sivapalasingam S; Soin AS; Staplin N; Stone JH; Strohbehn GW; Sunden-Cullberg J; Torre-Cisneros J; Tsai LW; van Hoogstraten H; van Meerten T; Veiga VC; Westerweel PE; Murthy S; Diaz JV; Marshall JC; Sterne JAC
JAMA; 2021 Aug; 326(6):499-518. PubMed ID: 34228774
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
[TBL] [Abstract][Full Text] [Related]
14. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
16. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
Kow CS; Hasan SS
Eur J Clin Pharmacol; 2021 Aug; 77(8):1089-1094. PubMed ID: 33532896
[TBL] [Abstract][Full Text] [Related]
17. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
Zhang J; Chen C; Yang Y; Yang J
Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
